Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

To watch more expert insights and analysis ... Pfizer, as it competes with the likes of Novo Nordisk and Eli Lilly in the weight loss drug space. 00:43 Speaker B Plus, Nvidia announcing a big ...

Discover how Viking Therapeutics, Inc.'s VK2735 and VK2809 target obesity and NASH markets. Click for my updated look at VKTX ...

Brad Smith and Madison Mills take a closer look at some of today's trending tickers. Pfizer (PFE) discontinued its obesity ...

Pfizer has announced that it is discontinuing ... We sell different types of products and services to both investment professionals and individual investors. These products and services are ...

Its statement also suggested the patient’s liver enzymes were elevated. That often is indicative of damage to cells in the organ, according to the Cleveland Clinic. Pfizer told CNBC that the trial ...

Pfizer Inc. (PFE) is currently at $22.83, up $0.71 or 3.19% --Would be highest close since April 4, 2025, when it closed at $22.97 --On pace for largest percent increase since Dec. 17, 2024, when it ...

And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls ... new medicines to patients,” Pfizer’s Chief Scientific Officer ...

Factors driving the market include rising disease prevalence, innovative therapies, and gene-based treatment breakthroughs. Key players like H Lundbe ...

The COVID-19 vaccine continues to save lives, proving the vaccination strategy paid off and was a worthwhile national ...

A string of pharmaceutical bosses attended a three-hour dinner at Donald Trump’s Mar-a-Lago resort in Florida in December.

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million in cash and a $350 million equity investment – with another $1.4 ...